|
Showing 1 - 12 of
12 matches in All Departments
History of Modern Biotechnology, devided into two volumes (69 and 70), is devoted to the developments in different countries. A.L. Demain, A. Fang: The Natural Functions of Secondary Metabolites.- T. Beppu: Development of Applied Microbiology to Modern Biotechnology in Japan.- H. Kumagai: Microbial Production of Amino Acids in Japan.- T.K. Ghose, V.S. Bisaria: Development of Biotechnology in India.- M. Roehr: History of Biotechnology in Austria.- J. Hollo, U.P. Kralovánszky: Biotechnology in Hungary.- A. Fiechter: Biotechnology in Switzerland and a Glance at Germany.
The biotechnology business in India with an increase from USD 500
million in 1997 and reaching an estimated USD 1 billion next year
health related prod ucts accounting for 60%, agro and veterinary
products together 15%, and con tract R&D, reagents, devices and
supplies adding up to the remaining 25% of which the diagnostics
share was about 10% of the total surely presented an encouraging
picture even five years ago. While volumes have increased, the pat
tern has not. According to a report, prepared by McKinsey & Co,
India's Phar maceutical industry including domestic and export
sales and contract services totals nearly USD 5 billion.
Furthermore, the company optimistically projects the growth to a
factor of five fold only if both the industry and the government
are able to put in place achievable solutions that must take care
of the formida ble obstacles preventing further growth. If this
assessment is correct, then the established transformation made by
IT growth should also provide the confi dence required by the high
expectations for biotechnology which have arisen in the country in
recent years. Some contributors to this are overenthusiastic these
are bureaucrats, some retired scientists and of course the
complacent politicians who have the least knowledge of what the new
biotechnology is all about. However, there are clear indications of
biotechnology growth demon strated by a few but rapidly expanding
biotech companies such as Biocon Ltd, Shantha Biotech (P) Ltd, Dr.
The biotechnology business in India with an increase from USD 500
million in 1997 and reaching an estimated USD I billion next year
health related prod ucts accounting for 60%, agro and veterinary
products together 15%, and con tract R&D, reagents, devices and
supplies adding up to the remaining 25% of which the diagnostics
share was about 10% of the total surely presented an encouraging
picture even five years ago. While volumes have increased, the pat
tern has not. According to a report, prepared by McKinsey & Co,
India's Phar maceutical industry including domestic and export
sales and contract services totals nearly USD 5 billion.
Furthermore, the company optimistically projects the growth to a
factor of five fold only if both the industry and the government
are able to put in place achievable solutions that must take care
of the formida ble obstacles preventing further growth. If this
assessment is correct, then the established transformation made by
IT growth should also provide the confi dence required by the high
expectations for biotechnology which have arisen in the country in
recent years. Some contributors to this are overenthusiastic these
are bureaucrats, some retired scientists and of course the
complacent politicians who have the least knowledge of what the new
biotechnology is all about. However, there are clear indications of
biotechnology growth demon strated by a few but rapidly expanding
biotech companies such as Biocon Ltd, Shantha Biotech (P) Lid, Dr.
History of Modern Biotechnology, devided into two volumes (69 and
70), is devoted to the developments in different countries. A.L.
Demain, A. Fang: The Natural Functions of Secondary Metabolites.-
T. Beppu: Development of Applied Microbiology to Modern
Biotechnology in Japan.- H. Kumagai: Microbial Production of Amino
Acids in Japan.- T.K. Ghose, V.S. Bisaria: Development of
Biotechnology in India.- M. Roehr: History of Biotechnology in
Austria.- J. Hollo, U.P. Kralovanszky: Biotechnology in Hungary.-
A. Fiechter: Biotechnology in Switzerland and a Glance at Germany."
The biotechnology business in India with an increase from USD 500
million in 1997 and reaching an estimated USD 1 billion next year
health related prod ucts accounting for 60%, agro and veterinary
products together 15%, and con tract R&D, reagents, devices and
supplies adding up to the remaining 25% of which the diagnostics
share was about 10% of the total surely presented an encouraging
picture even five years ago. While volumes have increased, the pat
tern has not. According to a report, prepared by McKinsey & Co,
India's Phar maceutical industry including domestic and export
sales and contract services totals nearly USD 5 billion.
Furthermore, the company optimistically projects the growth to a
factor of five fold only if both the industry and the government
are able to put in place achievable solutions that must take care
of the formida ble obstacles preventing further growth. If this
assessment is correct, then the established transformation made by
IT growth should also provide the confi dence required by the high
expectations for biotechnology which have arisen in the country in
recent years. Some contributors to this are overenthusiastic these
are bureaucrats, some retired scientists and of course the
complacent politicians who have the least knowledge of what the new
biotechnology is all about. However, there are clear indications of
biotechnology growth demon strated by a few but rapidly expanding
biotech companies such as Biocon Ltd, Shantha Biotech (P) Ltd, Dr.
The biotechnology business in India with an increase from USD 500
million in 1997 and reaching an estimated USD I billion next year
health related prod ucts accounting for 60%, agro and veterinary
products together 15%, and con tract R&D, reagents, devices and
supplies adding up to the remaining 25% of which the diagnostics
share was about 10% of the total surely presented an encouraging
picture even five years ago. While volumes have increased, the pat
tern has not. According to a report, prepared by McKinsey & Co,
India's Phar maceutical industry including domestic and export
sales and contract services totals nearly USD 5 billion.
Furthermore, the company optimistically projects the growth to a
factor of five fold only if both the industry and the government
are able to put in place achievable solutions that must take care
of the formida ble obstacles preventing further growth. If this
assessment is correct, then the established transformation made by
IT growth should also provide the confi dence required by the high
expectations for biotechnology which have arisen in the country in
recent years. Some contributors to this are overenthusiastic these
are bureaucrats, some retired scientists and of course the
complacent politicians who have the least knowledge of what the new
biotechnology is all about. However, there are clear indications of
biotechnology growth demon strated by a few but rapidly expanding
biotech companies such as Biocon Ltd, Shantha Biotech (P) Lid, Dr.
|
You may like...
Tenet
John David Washington, Robert Pattinson
Blu-ray disc
(1)
R52
R44
Discovery Miles 440
Gloria
Sam Smith
CD
R383
Discovery Miles 3 830
Loot
Nadine Gordimer
Paperback
(2)
R383
R318
Discovery Miles 3 180
|